BPCR.L
BioPharma Credit PLC
Price:  
0.88 
USD
Volume:  
820,218
United Kingdom | Capital Markets

BPCR.L WACC - Weighted Average Cost of Capital

The WACC of BioPharma Credit PLC (BPCR.L) is 8.9%.

The Cost of Equity of BioPharma Credit PLC (BPCR.L) is 13.7%.
The Cost of Debt of BioPharma Credit PLC (BPCR.L) is 5%.

RangeSelected
Cost of equity11.3% - 16.1%13.7%
Tax rate19.0% - 19.0%19%
Cost of debt5.0% - 5.0%5%
WACC7.7% - 10.1%8.9%
WACC

BPCR.L WACC calculation

CategoryLowHigh
Long-term bond rate4.0%4.5%
Equity market risk premium5.5%6.5%
Adjusted beta1.321.71
Additional risk adjustments0.0%0.5%
Cost of equity11.3%16.1%
Tax rate19.0%19.0%
Debt/Equity ratio
11
Cost of debt5.0%5.0%
After-tax WACC7.7%10.1%
Selected WACC8.9%

BPCR.L's CAPM model and how its cost of Equity is calculated

The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.

This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.

Here’s how we figure out the cost of equity for BPCR.L:

cost_of_equity (13.70%) = risk_free_rate (4.25%) + equity_risk_premium (6.00%) * adjusted_beta (1.32) + risk_adjustments (0.25%)

We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.